ABSTRACT
Molecular imaging and targeting using nanobodies
Our research is focused on the development of radiolabeled cancer targeting probes to image and treat cancer. We apply probes that are based on single domain antibody fragments derived from heavy chain only antibodies also called nanobodies or single domain antibody fragments (sdAbs). We developed nanobodies against the human epidermal growth factor receptor subtype 2 (HER2) as a theranostic tool for breast cancer. Recently these probes were evaluated in a phase I clinical trials. The presentation will give an overview of the research and development of nanobody theranostics.
BIO
Tony Lahoutte is head of the department of nuclear medicine at UZ Brussel and head of the molecular imaging research unit at the Vrije Universiteit Brussel (VUB) in Belgium. In 2014 he co-founded the company Camel-IDS NV that is developing a pipeline of radio-immuno therapeutics He obtained his medical degree in 1998 and started his research activities in combination with a residency program in nuclear medicine. His current research is focused on the development and clinical translation of molecular imaging probes and targeted radionuclide therapies for the detection and treatment of cancer.
Molecular imaging and targeting using nanobodies
Our research is focused on the development of radiolabeled cancer targeting probes to image and treat cancer. We apply probes that are based on single domain antibody fragments derived from heavy chain only antibodies also called nanobodies or single domain antibody fragments (sdAbs). We developed nanobodies against the human epidermal growth factor receptor subtype 2 (HER2) as a theranostic tool for breast cancer. Recently these probes were evaluated in a phase I clinical trials. The presentation will give an overview of the research and development of nanobody theranostics.
BIO
Tony Lahoutte is head of the department of nuclear medicine at UZ Brussel and head of the molecular imaging research unit at the Vrije Universiteit Brussel (VUB) in Belgium. In 2014 he co-founded the company Camel-IDS NV that is developing a pipeline of radio-immuno therapeutics He obtained his medical degree in 1998 and started his research activities in combination with a residency program in nuclear medicine. His current research is focused on the development and clinical translation of molecular imaging probes and targeted radionuclide therapies for the detection and treatment of cancer.